Background Chronic obstructive pulmonary disease (COPD) is a chronic, irreversible
disease and a leading cause of worldwide morbidity and mortality. In Canada, COPD is the …

Writing on the definition of chronic obstructive pulmonary disease (COPD), Dr Nicholas
Gross once compared it to defining love,“everybody knows what it is, but each individual …

Background Real-world prescription pathways leading to triple therapy (TT)(inhaled
corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting …

Chronic obstructive pulmonary disease (COPD) is a major public health problem in India.
Although several International guidelines for diagnosis and management of COPD are …

Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who
experience recurrent exacerbations are particularly at risk of poor outcomes and present a …

Educational aims To discuss fundamental questions relating to the use of bronchodilators
that can lead to an optimisation of their utilisation. To describe new bronchodilators that …

This real-world study compared the effectiveness of triple therapy (TT; long-acting
muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled …

There is currently no consensus on the treatment sequence in chronic obstructive pulmonary
disease (COPD), although it is recognized that early diagnosis is of paramount importance …

Introduction: Inhaled bronchodilators are the mainstay of the current management of COPD
at all stages of the disease, and are critical in the symptomatic management of asthma …

Introduction: Long-acting muscarinic receptor antagonists (LAMAs) are central to the
treatment of chronic obstructive pulmonary disease (COPD) because of the important role of …